Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy.

Foster CC, Lee AY, Furtado LV, Hart J, Alpert L, Xiao SY, Hyman NH, Sharma MR, Liauw S.

PLoS One. 2018 Mar 9;13(3):e0194234. doi: 10.1371/journal.pone.0194234. eCollection 2018.

2.

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ.

J Clin Oncol. 2018 Feb 13:JCO2017762229. doi: 10.1200/JCO.2017.76.2229. [Epub ahead of print]

PMID:
29437535
3.

Strategies to manage chemotherapy-induced peripheral neuropathy.

Sharma MR.

Clin Adv Hematol Oncol. 2017 Dec;15(12):938-940. No abstract available.

PMID:
29315285
4.

A Simple Glue-Tray Guide for Precise Miniscrew Insertion.

Singh S, Sharma MR, Sandhu N, Ranaut A.

J Clin Orthod. 2017 Jun;51(6):261-262. No abstract available.

PMID:
29059064
5.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

PMID:
28978556
6.

Effect of long-term treatment with tumour necrosis factor-α inhibitors on single-dose ultraviolet-induced changes in human skin.

Kim HJ, Langenhan JL, Robinson ES, Privette E, Achtman JC, Mitrani RA, Zeidi M, Sharma MR, Feng R, Nevas JL, Calianno C, Okawa J, Taylor L, Pappas-Taffer L, Werth VP.

Br J Dermatol. 2017 Dec;177(6):1762-1764. doi: 10.1111/bjd.15897. Epub 2017 Nov 15. No abstract available.

PMID:
28815549
7.

PharmGKB summary: pazopanib pathway, pharmacokinetics.

Thorn CF, Sharma MR, Altman RB, Klein TE.

Pharmacogenet Genomics. 2017 Aug;27(8):307-312. doi: 10.1097/FPC.0000000000000292. No abstract available.

PMID:
28678138
8.

Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms.

Wood K, Byron E, Janisch L, Salgia R, Sharma MR.

Am J Clin Oncol. 2017 Jun 26. doi: 10.1097/COC.0000000000000400. [Epub ahead of print]

PMID:
28654574
9.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

PMID:
28620884
10.

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ.

Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.

PMID:
28105566
11.

Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.

Toffoli G, Sharma MR, Marangon E, Posocco B, Gray E, Mai Q, Buonadonna A, Polite BN, Miolo G, Tabaro G, Innocenti F.

Clin Cancer Res. 2017 Feb 15;23(4):918-924. doi: 10.1158/1078-0432.CCR-16-1012. Epub 2016 Aug 9.

12.

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Li CH, Bies RR, Wang Y, Sharma MR, Karovic S, Werk L, Edelman MJ, Miller AA, Vokes EE, Oto A, Ratain MJ, Schwartz LH, Maitland ML.

Clin Transl Sci. 2016 Feb;9(1):43-50. doi: 10.1111/cts.12384. Epub 2016 Jan 21.

13.

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.

Sharma MR, Ratain MJ.

Clin Cancer Res. 2016 Feb 1;22(3):527-9. doi: 10.1158/1078-0432.CCR-15-2005. Epub 2015 Oct 14.

14.

Pediatric Central Nervous System Tumors in Nepal: Retrospective Analysis and Literature Review of Low- and Middle-Income Countries.

Azad TD, Shrestha RK, Vaca S, Niyaf A, Pradhananga A, Sedain G, Sharma MR, Shilpakar SK, Grant GA.

World Neurosurg. 2015 Dec;84(6):1832-7. doi: 10.1016/j.wneu.2015.07.074. Epub 2015 Aug 14. Review.

PMID:
26283488
15.

The 55S mammalian mitochondrial ribosome and its tRNA-exit region.

Kaushal PS, Sharma MR, Agrawal RK.

Biochimie. 2015 Jul;114:119-26. doi: 10.1016/j.biochi.2015.03.013. Epub 2015 Mar 20. Review.

16.

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.

Xu JM, Liu XJ, Ge FJ, Lin L, Wang Y, Sharma MR, Liu ZY, Tommasi S, Paradiso A.

J Exp Clin Cancer Res. 2014 Dec 10;33:104. doi: 10.1186/s13046-014-0104-7.

17.

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials.

Sharma MR, Gray E, Goldberg RM, Sargent DJ, Karrison TG.

J Clin Oncol. 2015 Jan 1;33(1):36-41. doi: 10.1200/JCO.2014.57.2826. Epub 2014 Oct 27.

18.

Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus.

Akthar AS, Golden DW, Nanda R, Sharma MR, Te HS, Reddy KG, Zhang X, Malik R.

J Clin Oncol. 2016 Mar 20;34(9):e73-5. doi: 10.1200/JCO.2013.50.1643. Epub 2014 Jul 14. No abstract available.

PMID:
25024081
19.

Cryo-EM structure of the small subunit of the mammalian mitochondrial ribosome.

Kaushal PS, Sharma MR, Booth TM, Haque EM, Tung CS, Sanbonmatsu KY, Spremulli LL, Agrawal RK.

Proc Natl Acad Sci U S A. 2014 May 20;111(20):7284-9. doi: 10.1073/pnas.1401657111. Epub 2014 May 5. Erratum in: Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2736.

20.

Fragile X mental retardation protein regulates translation by binding directly to the ribosome.

Chen E, Sharma MR, Shi X, Agrawal RK, Joseph S.

Mol Cell. 2014 May 8;54(3):407-417. doi: 10.1016/j.molcel.2014.03.023. Epub 2014 Apr 17.

21.

Significance of level v lymph node dissection in clinically node positive oral cavity squamous cell carcinoma and evaluation of potential risk factors for level v lymph node metastasis.

Parikh DG, Chheda YP, Shah SV, Patel AM, Sharma MR.

Indian J Surg Oncol. 2013 Sep;4(3):275-9. doi: 10.1007/s13193-013-0241-z. Epub 2013 Apr 12.

22.

Multimodal Ayurvedic management for Sandhigatavata (Osteoarthritis of knee joints).

Sharma MR, Mehta CS, Shukla DJ, Patel KB, Patel MV, Gupta SN.

Ayu. 2013 Jan;34(1):49-55. doi: 10.4103/0974-8520.115447.

23.

Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.

Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR.

World J Gastroenterol. 2013 Jun 28;19(24):3899-903. doi: 10.3748/wjg.v19.i24.3899.

24.

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.

Sharma MR, Karrison TG, Kell B, Wu K, Turcich M, Geary D, Kang SP, Takebe N, Graham RA, Maitland ML, Schilsky RL, Ratain MJ, Cohen EE.

Clin Cancer Res. 2013 Jun 1;19(11):3059-67. doi: 10.1158/1078-0432.CCR-12-3829. Epub 2013 Apr 3.

25.

Estimation of renal cell carcinoma treatment effects from disease progression modeling.

Maitland ML, Wu K, Sharma MR, Jin Y, Kang SP, Stadler WM, Karrison TG, Ratain MJ, Bies RR.

Clin Pharmacol Ther. 2013 Apr;93(4):345-51. doi: 10.1038/clpt.2012.263. Epub 2012 Dec 27.

26.

Models of excellence: improving oncology drug development.

Sharma MR, Maitland ML, Ratain MJ.

Clin Pharmacol Ther. 2012 Nov;92(5):548-50. doi: 10.1038/clpt.2012.99.

27.

Structural aspects of mitochondrial translational apparatus.

Agrawal RK, Sharma MR.

Curr Opin Struct Biol. 2012 Dec;22(6):797-803. doi: 10.1016/j.sbi.2012.08.003. Epub 2012 Sep 6. Review.

28.

Why RECIST works and why it should stay--reply to counterpoint.

Sharma MR, Maitland ML, Ratain MJ.

Cancer Res. 2012 Oct 15;72(20):5158. doi: 10.1158/0008-5472.CAN-12-1988. Epub 2012 Sep 4. No abstract available.

29.

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.

Sharma MR, Maitland ML, Ratain MJ.

Cancer Res. 2012 Oct 15;72(20):5145-9; discussion 5150. doi: 10.1158/0008-5472.CAN-12-0058. Epub 2012 Sep 4.

30.

Third branchial anomaly: endoscopic management revisited.

Tanna M, Sharma MR, Patel B.

Ear Nose Throat J. 2012 Apr;91(4):150-1. No abstract available.

PMID:
22522351
31.

Resampling phase III data to assess phase II trial designs and endpoints.

Sharma MR, Karrison TG, Jin Y, Bies RR, Maitland ML, Stadler WM, Ratain MJ.

Clin Cancer Res. 2012 Apr 15;18(8):2309-15. doi: 10.1158/1078-0432.CCR-11-1815. Epub 2012 Jan 27.

32.

Role of randomized phase III trials in an era of effective targeted therapies.

Sharma MR, Schilsky RL.

Nat Rev Clin Oncol. 2011 Dec 6;9(4):208-14. doi: 10.1038/nrclinonc.2011.190. Review.

PMID:
22143142
33.

Intrasplenic transplantation of isolated adult rat hepatocytes: sex-reversal and/or suppression of the major constituent isoforms of cytochrome P450.

Sharma MR, Dworakowski W, Shapiro BH.

Toxicol Pathol. 2012;40(1):83-92. doi: 10.1177/0192623311425061. Epub 2011 Nov 14.

34.

Randomized phase II trials: a long-term investment with promising returns.

Sharma MR, Stadler WM, Ratain MJ.

J Natl Cancer Inst. 2011 Jul 20;103(14):1093-100. doi: 10.1093/jnci/djr218. Epub 2011 Jun 27. Review.

35.

Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.

Sharma MR, Wroblewski K, Polite BN, Knost JA, Wallace JA, Modi S, Sleckman BG, Taber D, Vokes EE, Stadler WM, Kindler HL.

Invest New Drugs. 2012 Jun;30(3):1211-5. doi: 10.1007/s10637-011-9681-x. Epub 2011 May 7.

36.

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.

Cohen EE, Sharma MR, Janisch L, Llobrera M, House L, Wu K, Ramirez J, Fleming GF, Stadler WM, Ratain MJ.

Eur J Cancer. 2011 Jul;47(10):1484-9. doi: 10.1016/j.ejca.2011.02.017. Epub 2011 Mar 23.

37.

Animal models of acute photodamage: comparisons of anatomic, cellular and molecular responses in C57BL/6J, SKH1 and Balb/c mice.

Sharma MR, Werth B, Werth VP.

Photochem Photobiol. 2011 May-Jun;87(3):690-8. doi: 10.1111/j.1751-1097.2011.00911.x. Epub 2011 Mar 9.

38.

GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy.

Sharma MR, Schilsky RL.

Nat Rev Clin Oncol. 2011 Feb;8(2):70-2. doi: 10.1038/nrclinonc.2010.219. Review.

PMID:
21278772
39.

PSRP1 is not a ribosomal protein, but a ribosome-binding factor that is recycled by the ribosome-recycling factor (RRF) and elongation factor G (EF-G).

Sharma MR, Dönhöfer A, Barat C, Marquez V, Datta PP, Fucini P, Wilson DN, Agrawal RK.

J Biol Chem. 2010 Feb 5;285(6):4006-14. doi: 10.1074/jbc.M109.062299. Epub 2009 Dec 4.

40.

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.

Sharma MR, Maitland ML, Ratain MJ.

Cancer J. 2009 Sep-Oct;15(5):426-30. doi: 10.1097/PPO.0b013e3181b9c5d5. Review.

PMID:
19826363
41.

Structure of a mitochondrial ribosome with minimal RNA.

Sharma MR, Booth TM, Simpson L, Maslov DA, Agrawal RK.

Proc Natl Acad Sci U S A. 2009 Jun 16;106(24):9637-42. doi: 10.1073/pnas.0901631106. Epub 2009 Jun 3.

42.

Airway management at floor level: a comparison of tracheal intubation using the Macintosh and Airtraq laryngoscopes.

Tong JL, Gait AJ, Woollard M, Nightingale PG, Sharma MR.

J R Army Med Corps. 2008 Mar;154(1):21-5.

PMID:
19090382
43.

UVB and proinflammatory cytokines synergistically activate TNF-alpha production in keratinocytes through enhanced gene transcription.

Bashir MM, Sharma MR, Werth VP.

J Invest Dermatol. 2009 Apr;129(4):994-1001. doi: 10.1038/jid.2008.332. Epub 2008 Nov 13.

44.

TNF-alpha production in the skin.

Bashir MM, Sharma MR, Werth VP.

Arch Dermatol Res. 2009 Jan;301(1):87-91. doi: 10.1007/s00403-008-0893-7. Epub 2008 Sep 30. Review.

PMID:
18825399
45.

Increased severity of alcoholic liver injury in female verses male rats: a microarray analysis.

Sharma MR, Polavarapu R, Roseman D, Patel V, Eaton E, Kishor PB, Nanji AA.

Exp Mol Pathol. 2008 Feb;84(1):46-58. Epub 2007 Oct 22.

PMID:
18062962
46.

Cryo-EM study of the spinach chloroplast ribosome reveals the structural and functional roles of plastid-specific ribosomal proteins.

Sharma MR, Wilson DN, Datta PP, Barat C, Schluenzen F, Fucini P, Agrawal RK.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19315-20. Epub 2007 Nov 27.

47.

Airway obstruction caused by PTEN hamartoma (Bannayan-Riley-Ruvalcaba) syndrome.

Sharma MR, Petty EM, Lesperance MM.

Arch Otolaryngol Head Neck Surg. 2007 Nov;133(11):1157-60. No abstract available.

PMID:
18025323
48.

Structural aspects of RbfA action during small ribosomal subunit assembly.

Datta PP, Wilson DN, Kawazoe M, Swami NK, Kaminishi T, Sharma MR, Booth TM, Takemoto C, Fucini P, Yokoyama S, Agrawal RK.

Mol Cell. 2007 Nov 9;28(3):434-45.

49.

Progression of the ribosome recycling factor through the ribosome dissociates the two ribosomal subunits.

Barat C, Datta PP, Raj VS, Sharma MR, Kaji H, Kaji A, Agrawal RK.

Mol Cell. 2007 Jul 20;27(2):250-61.

50.

Proteomics and electron microscopic characterization of the unusual mitochondrial ribosome-related 45S complex in Leishmania tarentolae.

Maslov DA, Spremulli LL, Sharma MR, Bhargava K, Grasso D, Falick AM, Agrawal RK, Parker CE, Simpson L.

Mol Biochem Parasitol. 2007 Apr;152(2):203-12. Epub 2007 Jan 20.

Supplemental Content

Loading ...
Support Center